Table 3.

Summary of locoregional or systemic chemotherapy for prevention of recurrence

Authors	Entry criteria	Treatment protocol	Sample size (Tx/Crl)	Observation time	DFS (Tx vs Ctl)	OS (Tx vs Ctl)	Conclusions
Yamamoto[20]	Liver cacner study	HCFU	67 (32/35)	6-10 years	Stage Ib cirrhosis	Stage I cirrhosis	Beneficial only to
	group of japan for	200 mg, bid			62% vs 32%	79% vs 70%	patients with
	UICC stage II HCCa				Stage II cirrhosis	Stage II cirrhosis	Stage I liver
					0% vs 0%c	59% vs 57%c	dys function
Kohno[21]	NA	UFT 300 mg, qd vs	88 (40/48)	NA	3-year	NA	Not effective
		UFT 300 mg, qd + A			37% vs 32%
		(ia, 40 mg/m2, once)
Ono[22]	NA	A 40 mg/m2 ia and	56 (29/27)	24 months	NA	NA	Not effective,with
		40 mg/m2 iv every					poor tolerance
		3 months for 2 years,
		and HCFU 300 mg
		qd for 2 years
Ueno[23]	NA	CDDP 50-80 mg and	21 (11/10)	> 1 year	70% vs 20%c	NA	Beneficial
		MMC 10 mg ia, 2-3 times

NA: Not available; A: Adriamycin or Epirubicin; ia: Intraarterially; iv: Intravenously; DFS: Disease free survival; OS: Overall survival.

^acomplete excision of a solitary tumor, less than 5 cm in diameter, with a tumor capsule and no vascular invasion to the first or second branches of the portal vein, or for other stage II tumors, complete removal with a surgical margin from the tumor edge of more than 1 cm;

^bsee the original paper;

^cestimated according to the figure in authors’ paper.